Skip to main content

Security report for kalarx.com

KALA Bio, Inc. · Healthcare · N/a

Medium risk. 6 critical or high findings in SSL/TLS, Security headers and 1 other check.

Security score

62/100

Risk levelMedium

0–100, higher is better. How it is calculated

KALA BIO is a clinical-stage biopharmaceutical company specializing in rare and serious eye diseases, with a focus on mesenchymal stem cell secretome therapies and an AI-driven platform called Researgency.ai for optimizing clinical trial data analysis. The company positions itself as an emerging leader in combining biopharma research with advanced AI technology to improve clinical research outcomes. The website is professionally designed, mobile-optimized, and provides clear navigation, targeting biopharmaceutical professionals and investors. However, the absence of WHOIS registration data for the domain raises concerns about domain legitimacy and ownership verification. Technically, the website uses modern JavaScript modules, custom CSS, and Google Fonts, delivering moderate performance and good mobile responsiveness. No CMS or hosting provider details are evident. The site lacks security headers and explicit security policies, and no analytics or tracking scripts were detected, indicating a minimal data collection approach. Privacy compliance is basic, with a privacy policy present but no cookie consent mechanism. From a security perspective, the site uses HTTPS (assumed but not confirmed from data), but lacks security headers and incident response information. No vulnerabilities or exposed sensitive data were detected. The missing WHOIS data and lack of security best practices reduce the overall security posture. Recommendations include improving security headers, adding cookie consent, and verifying domain registration details. Overall, the website is functional and professional but has gaps in domain legitimacy verification and security best practices. Strategic improvements in these areas will enhance trust and compliance.

Scanned

NIS2 and GDPR posture

GDPR outside view
53/ 100 · Medium
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

6 findings rated critical or high. Fix these first.

  1. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

  2. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing Strict-Transport-Security header

      Forces HTTPS connections

      What to do: Add "Strict-Transport-Security: max-age=31536000; includeSubDomains; preload"

      • CWE-319
      • OWASP A04:2025
      • ASVS V3.4.1
    • High

      Missing X-Frame-Options header

      Prevents clickjacking attacks

      What to do: Add "X-Frame-Options: DENY" or "X-Frame-Options: SAMEORIGIN"

    • High

      Missing Content-Security-Policy header

      Controls resources the browser is allowed to load

      What to do: Implement a Content-Security-Policy appropriate for your application

      • ASVS V3.4.3
      • OWASP Secure Headers: OWASP Secure Headers Project recommends Content-Security-Policy: default-src 'self'; form-action 'self'; base-uri 'self'; object-src 'none';…

  3. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Cookie Policy found

      GDPR requires clear information about cookie usage

      What to do: Add a dedicated cookie policy explaining cookie usage and purposes

Need hands-on remediation? Email guard@offseq.com

Keep watching kalarx.com

This scan found 25 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
57
Security headers
15
Email security
70
DNS health
75
Network security
100
GDPR outside view
53
Average
62

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

KALA BIO operates in the healthcare and technology sectors, focusing on biopharmaceutical R&D and AI platform development. The company leverages legacy clinical trial data and AI to innovate in ophthalmic disease treatment. Its business model combines drug development with enterprise AI solutions for clinical data analysis. Market positioning is that of an emerging leader in MSC-S therapies and AI-driven biopharma tools. The company targets biopharma professionals, investors, and researchers. The partnership with Researgency.ai indicates a strategic ecosystem approach. The NASDAQ mention suggests public company status, enhancing credibility. Growth indicators include pipeline development and AI platform rollout. However, lack of detailed company founding data and domain registration transparency are notable gaps.

Security posture

The website demonstrates a basic security posture with HTTPS assumed but not explicitly confirmed. No security headers such as Content-Security-Policy or X-Frame-Options were detected, which are important for mitigating common web attacks. There is no visible incident response or vulnerability disclosure information, and no security or privacy certifications are mentioned. The absence of cookie consent mechanisms despite a privacy policy indicates partial GDPR compliance. No analytics or tracking scripts reduce privacy risks but also limit user behavior insights. Overall, the security maturity is low to moderate, with recommendations to implement security headers, enhance privacy compliance, and publish incident response contacts to improve trust and resilience.

Recommendations

  1. Verify and publish accurate WHOIS domain registration information to improve legitimacy and trust.
  2. Implement standard security headers (CSP, X-Frame-Options, X-Content-Type-Options) to enhance web security.
  3. Add a cookie consent mechanism to comply with privacy regulations and improve user transparency.
  4. Publish explicit security policies and incident response contact information to demonstrate security readiness.
  5. Conduct regular security audits and vulnerability assessments to identify and remediate potential risks.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
KALA Bio, Inc.
Description
KALA BIO is a clinical-stage biopharmaceutical company focused on rare and serious eye diseases. The company develops mesenchymal stem cell secretome (MSC-S) therapies and an enterprise AI platform called Researgency.ai for biopharmaceutical data analysis and clinical trial optimization.
Key services
MSC-S therapies research, Enterprise AI platform development (Researgency.ai), Clinical trial data analysis
Content quality
good
Branding
consistent

Technology

Stack
JavaScript ES Modules, Google Fonts (Space Grotesk, IBM Plex Mono), Custom CSS, Video background
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
40/100

Analytics and tracking

Tracking level
minimal
Privacy practices
basic

Advertising

Transparency
poor

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
moderate

Key observations

  1. Website is fully accessible with no WAF or blocking detected.
  2. No WHOIS registration data found for the domain, which is unusual.
  3. Website content is focused on biopharmaceutical research and AI technology.
  4. No explicit contact emails or phone numbers found; contact is via form only.
  5. No cookie consent mechanism detected despite privacy policy presence.
  6. No security headers or explicit security policies found.
  7. No analytics or tracking scripts detected.
  8. External links limited to fonts.googleapis.com, researgency.ai, and LinkedIn.
  9. Website uses modern JavaScript modules and custom CSS.
  10. No structured data (JSON-LD, Open Graph) found in HTML head.
Technical notes

Notes

The website uses modern front-end technologies including JavaScript ES modules and Google Fonts, with custom CSS styling. The presence of a video background and responsive design indicates moderate technical sophistication. No CMS or backend platform is identifiable from the HTML. Performance is moderate, with no explicit indicators of optimization or CDN usage. Accessibility features are basic, with some ARIA labels present. SEO is supported by meta description and structured navigation links but lacks advanced structured data like JSON-LD or Open Graph tags. The absence of analytics or tracking scripts suggests minimal data collection. Overall, the technical infrastructure is adequate for a small biopharma company website but could benefit from enhanced performance optimization, accessibility improvements, and richer metadata for SEO.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with kalarx.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review kalarx.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.